Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP2K1 | Q02750 | 8/20 | 0.64 |
| ▸ | RAF1 | P04049 | 3/20 | 0.64 |
| ▸ | SRC | P12931 | 7/20 | 0.55 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.54 |
| ▸ | EGFR | P00533 | 6/20 | 0.53 |
| ▸ | ERBB2 | P04626 | 5/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4451083 | 0.92 | MAP2K1 (0.64) | MAP2K1RAF1SRCEGFRERBB2 | |
| SCHEMBL4443460 | 0.87 | EGFR (0.71) | MAP2K1SRCEGFRERBB2 | |
| SCHEMBL4453384 | 0.85 | MAP2K1 (0.65) | MAP2K1RAF1SRCPDE4BEGFR | |
| SCHEMBL2203629 | 0.82 | EGFR (0.66) | MAP2K1SRCEGFRERBB2 | |
| SCHEMBL2200378 | 0.82 | EGFR (0.66) | MAP2K1SRCEGFRERBB2 | |
| SCHEMBL4450594 | 0.81 | EGFR (0.64) | MAP2K1SRCEGFRERBB2 | |
| SCHEMBL2205725 | 0.81 | EGFR (0.65) | MAP2K1SRCEGFRERBB2 | |
| SCHEMBL4445445 | 0.80 | EGFR (0.61) | MAP2K1SRCEGFRERBB2 | |
| SCHEMBL4445590 | 0.80 | EGFR (0.61) | MAP2K1SRCEGFRERBB2 | |
| SCHEMBL4449201 | 0.79 | MAP2K1 (0.52) | MAP2K1RAF1SRCEGFRERBB2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1117659-B1 | SUBSTITUTED 3-CYANOQUINOLINES AS PROTEIN TYROSINE KINASES INHIBITORS | WYETH CORP (US) | 2003-12-03 | — | — | EP | claimed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | claimed |
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | WYETH (US) | 2009-12-31 | — | — | US | disclosed |
| US-6288082-B1 | COMPOUNDS SUCH AS 6,7-DIETHOXY-4-(INDAN-5-YLAMINO) -QUINOLINE-3-CARBONITRILE USED AS ANTINEOPLASTIC AGENTS AND IN THE TREATMENT OF POLYCYCSTIC KIDNEY DISEASE | AMERICAN CYANAMID COMPANY | 2001-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090325877-A1 | Combination Product of Receptor Tyrosine Kinase Inhibitor and Fatty Acid Synthase Inhibitor for Treating Cancer | FASN, FRS2, FGFR1 | MAP2K1 840/4885RAF1 126/4885SRC 9/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.